Champions Oncology, Inc. (CSBR)
$
5.87
-0.31 (-5.28%)
Key metrics
Financial statements
Free cash flow per share
-0.0966
Market cap
82.7 Million
Price to sales ratio
1.4112
Debt to equity
1.1770
Current ratio
0.9913
Income quality
-0.2020
Average inventory
0
ROE
6.5665
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Champions Oncology, Inc. develops and offers technology solutions and products aimed at personalizing oncology drug development and application within the United States. The company reported an income before tax of -$7,308,000.00 showcasing its pre-tax profitability. Its innovative Tumorgraft Technology Platform personalizes cancer care through the implantation of human tumors in immune-deficient mice, providing tailored insights for treatment. The net income ratio is -0.15 reflecting the company's profitability margin, while the operating income ratio is -0.15 indicating the company's operational profitability margin. The organization incurred an income tax expense of -$32,000.00 underscoring its tax obligations. Additionally, the company achieved a revenue of $50,155,000.00 indicating its niche market focus, and continues to expand its offerings through the Tumorgraft technology and Translational Oncology Solutions, assisting pharmaceutical and biotechnology firms in their drug development processes. Alongside these offerings, Champions Oncology provides Lumin Bioinformatics, a comprehensive software platform that consolidates extensive information from research services and clinical studies, available via annual subscriptions. The company effectively markets its products through the internet, word of mouth, and a dedicated sales force directed at both patients and physicians. Founded in 1985 and originally known as Champions Biotechnology, Inc., the company officially rebranded to Champions Oncology, Inc. in April 2011, and is headquartered in Hackensack, New Jersey. The stock is affordable at $6.18 making it suitable for budget-conscious investors. With a market capitalization of $81,163,903.00 the company is classified as a small-cap player. It operates within the Biotechnology industry, where it plays a vital role in enhancing the overall market landscape. However, it has a low average trading volume of 37,663.00 indicating lower market activity. Belonging to the Healthcare sector, Champions Oncology, Inc. is driving innovation and growth, continuously contributing to advances in personalized cancer care through its unique technology and solutions.
Is Champions Oncology, Inc. (CSBR) a good investment?
Investing in Champions Oncology, Inc. (CSBR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Champions Oncology, Inc. (CSBR)'s stock forecast?
Analysts predict Champions Oncology, Inc. stock to fluctuate between $3.60 (low) and $11.99 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Champions Oncology, Inc.'s market capitalization?
As of 2025-05-30, Champions Oncology, Inc.'s market cap is $81,163,903, based on 13,826,900 outstanding shares.
How does Champions Oncology, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Champions Oncology, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Champions Oncology, Inc. (CSBR) stock?
To buy Champions Oncology, Inc. (CSBR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CSBR. Place an order (Market, Limit, etc.).
What is the best time to invest in Champions Oncology, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Champions Oncology, Inc. stock ever split?
Champions Oncology, Inc.'s last stock split was 1:12 on 2015-08-12.
How did Champions Oncology, Inc. perform in the last earnings report?
Revenue: $50,155,000 | EPS: -$0.54 | Growth: 38.46%.
Where can I find Champions Oncology, Inc.'s investor relations reports?
Visit https://www.championsoncology.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Champions Oncology, Inc.?
You can explore historical data from here
What is the all-time high and low for Champions Oncology, Inc. stock?
All-time high: $14.68 (2021-03-16) | All-time low: $3.60 (2024-09-10).
What are the key trends affecting Champions Oncology, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2025 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Maj Soueidan - GeoInvesting George Marema - Pareto Ventures Operator Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2025 Earnings Call [Operator Instructions].
accesswire.com
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy. The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities.
seekingalpha.com
Champoins Oncology broke out of a multiyear downtrend following its Q2'25 earnings. Management has embarked on a one-way journey to reduce working capital and grow the business with zero incremental capital. This has succeeded and the business is now in a prime position to grow sales at 10% CAGR to CY'26 in my opinion.
seekingalpha.com
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2024 Earnings Conference Call December 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Operator Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2025 Earnings Call.
accesswire.com
HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024. Second Quarter and Recent Highlights: Total revenue increased 17% to $13.5 million Gross profit of $6.1 million; margin of 45% Net income of approximately $730,000 Adjusted EBITDA of $1.1 million Development of new data revenue stream First Half 2025 Highlights: Total revenue increased 14% to $27.6 million Gross profit of $13.1 million; margin of 47% Net income of $2.1 million Adjusted EBITDA of $3.2 million Ronnie Morris, CEO of Champions, commented, "Our second quarter's performance solidified our confidence in the Company's turnaround that we've been discussing the last several quarters.
accesswire.com
HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
See all news
